<DOC>
	<DOCNO>NCT00087607</DOCNO>
	<brief_summary>This study examine viral kinetics pharmacokinetics Pegasys plus ribavirin PEG-Intron plus ribavirin interferon-naive patient CHC . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>Peak Study - A Study Pegasys ( Peginterferon Alfa-2a ( 40KD ) ) Combination With Copegus ( Ribavirin ) Interferon-Naive Patients With Chronic Hepatitis C ( CHC ) .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>adult patient least 18 year age CHC infection , genotype 1 use 2 form contraception study men woman previous systemic therapy antiviral , antineoplastic , immunomodulatory agent medical condition associate chronic liver disease ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) decompensated liver disease woman pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>